Oncopeptides AB Statistics

Total Valuation

Oncopeptides AB has a market cap or net worth of SEK 331.87 million. The enterprise value is 357.69 million.

Market Cap	331.87M
Enterprise Value	357.69M

Important Dates

The next estimated earnings date is Thursday, August 21, 2025.

Earnings Date	Aug 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Oncopeptides AB has 225.76 million shares outstanding. The number of shares has increased by 116.81% in one year.

Current Share Class	211.26M
Shares Outstanding	225.76M
Shares Change (YoY)	+116.81%
Shares Change (QoQ)	-2.20%
Owned by Insiders (%)	0.71%
Owned by Institutions (%)	19.75%
Float	182.36M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.33
PB Ratio	-56.80
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.29
EV / Sales	8.98
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.37

Financial Position

The company has a current ratio of 3.22

Current Ratio	3.22
Quick Ratio	3.09
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.51
Interest Coverage	-24.37

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-92.72%
Return on Invested Capital (ROIC)	-148.84%
Return on Capital Employed (ROCE)	-217.56%
Revenue Per Employee	531,240
Profits Per Employee	-3.70M
Employee Count	80
Asset Turnover	0.21
Inventory Turnover	0.42

Taxes

In the past 12 months, Oncopeptides AB has paid 491,000 in taxes.

Income Tax	491,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -55.59% in the last 52 weeks. The beta is -0.59, so Oncopeptides AB's price volatility has been lower than the market average.

Beta (5Y)	-0.59
52-Week Price Change	-55.59%
50-Day Moving Average	1.82
200-Day Moving Average	1.76
Relative Strength Index (RSI)	27.36
Average Volume (20 Days)	844,718

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncopeptides AB had revenue of SEK 39.84 million and -277.57 million in losses. Loss per share was -1.41.

Revenue	39.84M
Gross Profit	37.55M
Operating Income	-276.76M
Pretax Income	-277.08M
Net Income	-277.57M
EBITDA	-274.28M
EBIT	-276.76M
Loss Per Share	-1.41

Full Income Statement

Balance Sheet

The company has 107.23 million in cash and 133.05 million in debt, giving a net cash position of -25.83 million or -0.11 per share.

Cash & Cash Equivalents	107.23M
Total Debt	133.05M
Net Cash	-25.83M
Net Cash Per Share	-0.11
Equity (Book Value)	-5.84M
Book Value Per Share	-0.03
Working Capital	102.40M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -261.53 million and capital expenditures -357,000, giving a free cash flow of -261.88 million.

Operating Cash Flow	-261.53M
Capital Expenditures	-357,000
Free Cash Flow	-261.88M
FCF Per Share	-1.16

Full Cash Flow Statement

Margins

Gross Margin	94.25%
Operating Margin	-694.63%
Pretax Margin	-695.43%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncopeptides AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-116.81%
Shareholder Yield	n/a
Earnings Yield	-83.64%
FCF Yield	-78.91%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3